Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: solidbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2025 | $16.00 | Buy | Truist |
| 12/13/2024 | $16.00 | Outperform | Wedbush |
| 12/10/2024 | $15.00 | Mkt Outperform | JMP Securities |
| 7/15/2024 | $10.00 → $15.00 | Neutral → Overweight | JP Morgan |
| 6/24/2024 | $12.00 | Market Perform → Outperform | Leerink Partners |
| 5/31/2024 | $20.00 | Overweight | Piper Sandler |
| 3/28/2024 | $40.00 | Outperform | William Blair |
| 3/15/2024 | $16.00 | Buy | Citigroup |
| 3/14/2024 | $8.00 → $20.00 | Neutral → Overweight | Piper Sandler |
| 12/8/2023 | $9.00 | Buy | H.C. Wainwright |
- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - FA: First-in-human clinical study of SGT-212 utilizing a dual route of administration to treat Friedreich's ataxia (FA) anticipated in 2H 2025 following recent FDA IND clearance - - CPVT: Submission of IND for SGT-501 on track for 1H 2025; the submission will expand clinical-stage portfolio to three unique candidates in diverse indications with significant unmet need - - Cash: Company enters 2025 with approximately $148.9 million in cash and investments1 as of 12/31/2024; expected to fund key strate
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeting with management during the conference may
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a
CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material t
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index® (NASDAQ:NBI) effective prior to the market open on Monday, December 23, 2024. The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is calculated under a modified capitalization-weighted methodolo
- Solid Biosciences to collaborate with Mayo Clinic's genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy platform and multiple next-generation cardiac gene therapy programs developed by Mayo Clinic's Windland Smith Rice Sudden Death Genomics Lab - CHARLESTOWN, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a collaboration with Mayo Clinic seeking to advance a cutting-edge AAV gene therapy platform for the development of nex
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement material t
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Citi's 2024 Global Healthcare Conference – Miami, FLBo Cumbo, President and CEO, will participate in a panel discussion titled "Neuromuscular Disorders" on Wednesday, December 4, 2024, at 1:00 p.m. ET. Piper Sandler 36th Annual Healthcare Conference – New York, NYMr. Cumbo and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat on Thursday, December 5, 2024, at 9:30 a.m. ET
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Combo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page. Institutional investors interested in meeti
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1 2025 - - Duchenne: Activities undertaken to accelerate development of SGT-003, including: expansion of study protocol in September 2024, activation of additional clinical sites in Q4 2024, additional manufacturing supply to support expanded trial enrollment - - CPVT: SGT-501 IND submission for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) on track for 1H 2025 - - Cash: Company ends Q3 2024 with approximately $171.1 million in cash, cash equivalents, and availab
SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)
SC 13G - Solid Biosciences Inc. (0001707502) (Subject)
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich's ataxia - - Dual route of administration enables direct delivery of AAV-based gene therapy to the cerebellum and heart to potentially address the most significant symptoms of the disease - - Phase 1b clinical trial initiation expected in 2H 2025 - - Company to hold a conference call tomorrow, January 8, 2025, at 8:30 AM ET - CHARLESTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today a
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patients with Duchenne; Anticipated dosing in late – 2023, subject to IND clearance - - Company ends 2022 with approximately $213.7 million in cash and investments; Anticipated cash runway into 2025 - CHARLESTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today reported financ
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - - Strong synergies expected by combining key assets, including product candidates for Duchenne muscular dystrophy, Friedreich's ataxia, BAG3 mediated dilated cardiomyopathy and other undisclosed cardiac diseases, novel capsid libraries, and personnel - - Combined company is expected to have approximately $215 million in cash and investments, which is expected to fund the combined company into 2025 and support attainment of key milestones for lead gene therapy programs - - Companies to Host Confere
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid development to continue, supported by new preclinical data; Company anticipates early-2023 Investigational New Drug (IND) submission for SGT-003 for Duchenne - - Strategy and resource alignment support funding of operations through important clinical milestones and into Q2 2024 - - Solid Biosciences reports first quarter 2022 financial results; Company to hold conference call at 8:00am ET today - CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a li
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results before the market opens on Wednesday, April 27, 2022. Management will host a conference call on the same date beginning at 8:00 a.m. ET to discuss the Company's financial results and a strategic update to develop SGT-001 and SGT-003 pipeline programs for Duchenne. A live webcast of the call will be available on the Company's website at www.solidbio.com under the "News & Events" tab in the Investor Relations secti
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
Truist initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00
Wedbush initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $16.00
JMP Securities initiated coverage of Solid Biosciences with a rating of Mkt Outperform and set a new price target of $15.00
JP Morgan upgraded Solid Biosciences from Neutral to Overweight and set a new price target of $15.00 from $10.00 previously
Leerink Partners upgraded Solid Biosciences from Market Perform to Outperform and set a new price target of $12.00
Piper Sandler resumed coverage of Solid Biosciences with a rating of Overweight and set a new price target of $20.00
William Blair initiated coverage of Solid Biosciences with a rating of Outperform and set a new price target of $40.00
Citigroup initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $16.00
Piper Sandler upgraded Solid Biosciences from Neutral to Overweight and set a new price target of $20.00 from $8.00 previously
H.C. Wainwright initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $9.00
144/A - Solid Biosciences Inc. (0001707502) (Subject)
144 - Solid Biosciences Inc. (0001707502) (Subject)
144 - Solid Biosciences Inc. (0001707502) (Subject)
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
8-K - Solid Biosciences Inc. (0001707502) (Filer)
S-8 - Solid Biosciences Inc. (0001707502) (Filer)
EFFECT - Solid Biosciences Inc. (0001707502) (Filer)
S-3/A - Solid Biosciences Inc. (0001707502) (Filer)
10-Q - Solid Biosciences Inc. (0001707502) (Filer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
4 - Solid Biosciences Inc. (0001707502) (Issuer)
– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash and investments; Anticipated cash runway through multiple important pipeline milestones and into 2025 – CHARLESTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the third quarter ended September 30, 2023, and provided a business update. "We are pleased with the continued advanceme
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid's focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medical Officer. "We are excited to welcome Dr. Brooks to Solid Biosciences during this pivotal time in our company's history, advancing towards the clinic with our next generation gene therapy for Duc
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection and transition manufacturing process to transient transfection for AVB-202 for Friedrich's Ataxia and AVB 401 in dilated cardiomyopathy continue – – Kevin Tan named Chief Financial Officer, experience to support execution of corporate strategy – – Company enters 2023 with approximately $214 million in cash and investments; expected to fund key strategic priorities into 2025 – CHARLESTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company d
CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the appointment of Kevin Tan, CFA, a seasoned industry professional, as Chief Financial Officer. "We are pleased to welcome Kevin at this important juncture in the company's evolution," said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. "Having previously worked with Kevin, I am confident his leadership, execution focus, and financial acumen will support the company's advancement towards key business objectives. Kevin has a deep understanding of capital markets and th
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior Vice President, Finance, effective August 16, 2021. Mr. Inbar brings to Solid an extensive background in public accounting, with expertise in building finance teams, designing financial processes, and implementing new systems. Most recently, he served as VP, Accounting and Corporate Controller at Syros Pharmaceuticals, Inc., a clinical stage biopharmaceutical company specializing in the discovery and development
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulatory Officer, effective June 1, 2021. Dr. Barilero brings three decades of experience as a strategic executive in the healthcare industry, successfully designing innovative and integrated regulatory pathways that gained regulatory approvals for new molecular entities in various areas of unmet medical needs across all phases of development in the U.S., EU, Switzerland, China, Japan and Brazil. “Dr. Barilero comes t
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today announced the appointment of Georgia Keresty, Ph.D., M.P.H., to the company's Board of Directors. "Dr. Keresty's experience as a scientific and operational leader in our industry will be a great asset to Intellia as we continue to advance our research programs, expand our manufacturing capabilities and move towards delivering potentially curative therapies to patients globally," said Intellia President and Chief Executive Officer John Leonard, M.D. Dr. Ke
-Adding senior level experience to help advance programs for Duchenne muscular dystrophy- CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced today that Erin Powers Brennan has joined the company as Chief Legal Officer and Joel Schneider, Ph.D., has been promoted to Chief Operating Officer. The Company also announced the appointment of Clare Kahn, Ph.D., and Georgia Keresty, Ph.D., M.P.H., to its Board of Directors. “Erin and Joel are two highly respected industry leaders who, in addition to their business acumen, share ou